ArticleGeroScience2026
Hyaluronan deficiency disrupts endothelial glycocalyx integrity and contributes to age-related arterial dysfunction.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aging is accompanied by arterial dysfunction, defined by impaired endothelial function and increased large artery stiffness, yet the contribution of the endothelial glycocalyx (eGC) and its constituent, hyaluronan (HA), to this process remains incompletely understood. We tested the hypothesis that decreasing endothelial HA synthesis via a reduction in endothelial-specific HA synthase 2 (HAS2) compromises eGC integrity and contributes to arterial dysfunction with advancing age. Both endothelial-specific HAS2 reduction and aging impair eGC integrity, evidenced by impaired barrier function and reduced eGC thickness in vivo, and aging led to a reduction in circulating HA and an increase in syndecan-1. Similar to aging, reduced endothelial HA selectively attenuated flow-induced endothelium-dependent dilation (EDD) and eNOS activation, whereas agonist-induced EDD was preserved in young arteries despite the concomitant eGC dysfunction. In parallel, reduced HAS2 expression and advancing age were each associated with increased aortic stiffness and adverse arterial remodeling, including excessive collagen deposition and reduced elastin. Collectively, these findings identify endothelial HA as a key determinant of eGC integrity and endothelial function, linking impaired HA availability to the development of arterial dysfunction with advancing age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.